免疫檢查點（checkpoint）是指在免疫細胞上表達、能調節免疫激活程度的一系列分子，它們對防止自身免疫（免疫功能發生異常，對正常細胞發動攻擊）作用的發生，起著重要作用。
人體的免疫功能收到激發時會活化，但不會過度活化，因為”免疫檢查點分子“的重要功能之一就是類似汽車的剎車系統，在免疫系統活化時能夠及時”剎車“，使免疫系統的活化保持在正常的范圍之內，這樣，免疫系統就不會過度活化。
免疫檢查點分子的表達和功能異常是很多疾病發生的重要原因之一，比如免疫檢查點分子過度表達或功能過強，免疫功能受到抑制，機體的免疫力就低下；反之，免疫檢查點分子的這種免疫抑制功能如果太差，機體的免疫功能也會異常。
腫瘤細胞會表達一些物質，來激活免疫檢查點，后者一旦被激活，就如同踩下”剎車“，使抗原不能被提呈至T細胞，阻斷了腫瘤免疫環中的提呈抗原過程，從而抑制T細胞的免疫功能，自己就能逃脫監視、存活下來。
| 靶點 | 產品貨號 | 產品名稱 |
PD1-PDL1
|
GM-81957AB
|
Anti-Canine_PD1 mIgG2a Antibody(4F12-E6)
|
|
PD1-PDL1
|
GM-79817AB
|
Anti-PD-L2 hIgG1 Antibody(Hz25G4-1.1)
|
|
PD1-PDL1
|
GM-32251AB
|
Anti-H_PDCD1LG2 mIgG1 Antibody(3G2)
|
|
PD1-PDL1
|
GM-60293AB
|
Anti-CTLA-4/PD-1 hIgG1 Bispecific Antibody(Cadonilimab)
|
|
PD1-PDL1
|
GM-52674AB
|
Anti-PD1 hIgG4 Antibody(Pembrolizumab)
|
|
PD1-PDL1
|
GM-28957AB
|
Anti-H_PDCD1(PD1) hIgG1 Antibody(Budigalimab)
|
|
CD40
|
GM-86199AB
|
Anti-H_CD40 hIgG1 Antibody(ravagalimab)
|
|
CD40
|
GM-83977AB
|
Anti-H_CD40L hIgG1 Antibody(dapirolizumab)
|
|
CD40
|
GM-83978AB
|
Anti-H_CD40L hIgG1 Antibody(frexalimab)
|
|
CD40
|
GM-24025AB
|
Anti-H_CD40 hIgG1 Antibody(APX005M)
|
|
OX40
|
GM-82533AB
|
Anti-OX40L hIgG4 Antibody(Amlitelimab)
|
|
OX40
|
GM-23373AB
|
Anti-H_OX40 hIgG2 Antibody(Ivuxolimab)
|
|
Lag3
|
GM-51650AB
|
Anti-Lag3 hIgG4 Antibody(Relatlimab)
|
|
Lag3
|
GM-51647AB
|
Anti-Lag3 hIgG4 Antibody(IMP-7)
|
|
Lag3
|
GM-28753AB
|
Anti-H_LAG3 hIgG4 Antibody(Mavezelimab)
|
|
CD27-CD70
|
GM-24024AB
|
Anti-H_CD70 hIgG1 Antibody(Cusatuzumab)
|
|
CD27-CD70
|
GM-31740AB
|
Anti-H_CD274(PDL1) hIgG1 Antibody(Atezolizumab)
|
|
CD47-SIRPα
|
GM-27657AB
|
Anti-CD47 hIgG4 Antibody(5F9)
|
|
CD28
|
GM-52277AB
|
Anti-CD28 hIgG4 Antibody(FR104)
|
|
CD28
|
GM-27197AB
|
Anti-H_CD28 hIgG4 Antibody(Theralizumab)
|
|
CD112-CD112R
|
GM-30125AB
|
Anti-H_NECTIN2(CD112) hIgG1 Antibody
|
|
CD112-CD112R
|
GM-48167AB
|
Anti-CD112R hIgG1 Antibody(SRF813)
|
|
HVEM
|
GM-49928AB
|
Anti-TNFRSF14(HVEM) hIgG4 Antibody
|
|
TREM
|
GM-30244AB
|
Anti-TREM2 hIgG1 Antibody
|
|
TREM
|
GM-22998AB
|
Anti-H_TREM2 Rat_IgG2b Antibody
|
|
TREM
|
GM-48593AB
|
Anti-H_TREM2 hIgG4 Antibody
|
|
HAVCR2(TIM3)
|
GM-50627AB
|
Anti-TIM3 hIgG2 Antibody(M6903)
|
|
HAVCR2(TIM3)
|
GM-27128AB
|
Anti-H_HAVCR2(TIM3) hIgG4 Antibody(Sabatolimab)
|
|
BTLA-HVEM
|
GM-50103AB
|
Anti-BTLA hIgG4 Antibody(22B3)
|
|
BTLA-HVEM
|
GM-28675AB
|
Anti-BTLA hIgG4 Antibody(Icatolimab)
|
|
CD200-CD200R
|
GM-48495AB
|
Anti-H_CD200 hIgG Antibody(Samalizumab)
|
|
CD200-CD200R
|
GM-48346AB
|
Anti-H_CD200R hIgG1 Antibody(huDX182)
|
|
CD200-CD200R
|
GM-48237AB
|
Anti-CD200R hIgG4 Antibody(I-4P)
|
|
CD200-CD200R
|
GM-48240AB
|
Anti-CD200R hIgG4 Antibody
|
|
CTLA4:CD80:CD86
|
GM-46075AB
|
Anti-H_CD80 hIgG1 Antibody(Galiximab)
|
|
CTLA4:CD80:CD86
|
GM-27203AB
|
Anti-H_CTLA-4 hIgG1 Antibody(Ipilimumab)
|
|
SIGLEC8
|
GM-28730AB
|
Anti-H_SIGLEC8 hIgG1 Antibody(1H10)
|
|
4-1BB
|
GM-26840AB
|
Anti-H_4-1BB hIgG2 Antibody(Utomilumab)
|
|
4-1BB
|
GM-28954AB
|
Anti-H_TNFRSF9(4-1BB) hIgG4 Antibody (Urelumab)
|
|
SIGLEC15
|
GM-24717AB
|
Anti-Siglec15 mIgG2a Antibody(5G12)
|
|
TIGIT-PVR-CD155
|
GM-24029AB
|
Anti-H_Tigit hIgG1 Antibody(Vibostolimab)
|
|
TIGIT-PVR-CD155
|
GM-27659AB
|
Anti-H_PVRIG hIgG1 Antibody
|
|
SLC39A6
|
GM-26839AB
|
Anti-H_SLC39A6 hIgG1 Antibody(Ladiratuzumab)
|
|
SIGLEC9
|
GM-31414AB
|
Anti-siglec9 mIgG1 Antibody(2D4)
|
|
VTCN1(B7H4)
|
GM-24028AB
|
Anti-H_B7H4(VTCN1) hIgG1 Antibody(FPA150)
|
|
VTCN1(B7H4)
|
GM-86662MAB
|
Anti-H_B7H4 hIgG1 Reference Antibody(FPA150)
|
| 靶點 | 產品貨號 | 產品名稱 |
|
PD1-PDL1
|
GM-81957AB
|
Anti-Canine_PD1 mIgG2a Antibody(4F12-E6)
|
|
PD1-PDL1
|
GM-79817AB
|
Anti-PD-L2 hIgG1 Antibody(Hz25G4-1.1)
|
|
PD1-PDL1
|
GM-32251AB
|
Anti-H_PDCD1LG2 mIgG1 Antibody(3G2)
|
|
PD1-PDL1
|
GM-60293AB
|
Anti-CTLA-4/PD-1 hIgG1 Bispecific Antibody(Cadonilimab)
|
|
PD1-PDL1
|
GM-52674AB
|
Anti-PD1 hIgG4 Antibody(Pembrolizumab)
|
|
PD1-PDL1
|
GM-28957AB
|
Anti-H_PDCD1(PD1) hIgG1 Antibody(Budigalimab)
|
|
CD40
|
GM-86199AB
|
Anti-H_CD40 hIgG1 Antibody(ravagalimab)
|
|
CD40
|
GM-83977AB
|
Anti-H_CD40L hIgG1 Antibody(dapirolizumab)
|
|
CD40
|
GM-83978AB
|
Anti-H_CD40L hIgG1 Antibody(frexalimab)
|
|
CD40
|
GM-24025AB
|
Anti-H_CD40 hIgG1 Antibody(APX005M)
|
|
OX40
|
GM-82533AB
|
Anti-OX40L hIgG4 Antibody(Amlitelimab)
|
|
OX40
|
GM-23373AB
|
Anti-H_OX40 hIgG2 Antibody(Ivuxolimab)
|
|
Lag3
|
GM-51650AB
|
Anti-Lag3 hIgG4 Antibody(Relatlimab)
|
|
Lag3
|
GM-51647AB
|
Anti-Lag3 hIgG4 Antibody(IMP-7)
|
|
Lag3
|
GM-28753AB
|
Anti-H_LAG3 hIgG4 Antibody(Mavezelimab)
|
|
CD27-CD70
|
GM-24024AB
|
Anti-H_CD70 hIgG1 Antibody(Cusatuzumab)
|
|
CD27-CD70
|
GM-31740AB
|
Anti-H_CD274(PDL1) hIgG1 Antibody(Atezolizumab)
|
|
CD47-SIRPα
|
GM-27657AB
|
Anti-CD47 hIgG4 Antibody(5F9)
|
|
CD28
|
GM-52277AB
|
Anti-CD28 hIgG4 Antibody(FR104)
|
|
CD28
|
GM-27197AB
|
Anti-H_CD28 hIgG4 Antibody(Theralizumab)
|
|
CD112-CD112R
|
GM-30125AB
|
Anti-H_NECTIN2(CD112) hIgG1 Antibody
|
|
CD112-CD112R
|
GM-48167AB
|
Anti-CD112R hIgG1 Antibody(SRF813)
|
|
HVEM
|
GM-49928AB
|
Anti-TNFRSF14(HVEM) hIgG4 Antibody
|
|
TREM
|
GM-30244AB
|
Anti-TREM2 hIgG1 Antibody
|
|
TREM
|
GM-22998AB
|
Anti-H_TREM2 Rat_IgG2b Antibody
|
|
TREM
|
GM-48593AB
|
Anti-H_TREM2 hIgG4 Antibody
|
|
HAVCR2(TIM3)
|
GM-50627AB
|
Anti-TIM3 hIgG2 Antibody(M6903)
|
|
HAVCR2(TIM3)
|
GM-27128AB
|
Anti-H_HAVCR2(TIM3) hIgG4 Antibody(Sabatolimab)
|
|
BTLA-HVEM
|
GM-50103AB
|
Anti-BTLA hIgG4 Antibody(22B3)
|
|
BTLA-HVEM
|
GM-28675AB
|
Anti-BTLA hIgG4 Antibody(Icatolimab)
|
|
CD200-CD200R
|
GM-48495AB
|
Anti-H_CD200 hIgG Antibody(Samalizumab)
|
|
CD200-CD200R
|
GM-48346AB
|
Anti-H_CD200R hIgG1 Antibody(huDX182)
|
|
CD200-CD200R
|
GM-48237AB
|
Anti-CD200R hIgG4 Antibody(I-4P)
|
|
CD200-CD200R
|
GM-48240AB
|
Anti-CD200R hIgG4 Antibody
|
|
CTLA4:CD80:CD86
|
GM-46075AB
|
Anti-H_CD80 hIgG1 Antibody(Galiximab)
|
|
CTLA4:CD80:CD86
|
GM-27203AB
|
Anti-H_CTLA-4 hIgG1 Antibody(Ipilimumab)
|
|
SIGLEC8
|
GM-28730AB
|
Anti-H_SIGLEC8 hIgG1 Antibody(1H10)
|
|
4-1BB
|
GM-26840AB
|
Anti-H_4-1BB hIgG2 Antibody(Utomilumab)
|
|
4-1BB
|
GM-28954AB
|
Anti-H_TNFRSF9(4-1BB) hIgG4 Antibody (Urelumab)
|
|
SIGLEC15
|
GM-24717AB
|
Anti-Siglec15 mIgG2a Antibody(5G12)
|
|
TIGIT-PVR-CD155
|
GM-24029AB
|
Anti-H_Tigit hIgG1 Antibody(Vibostolimab)
|
|
TIGIT-PVR-CD155
|
GM-27659AB
|
Anti-H_PVRIG hIgG1 Antibody
|
|
SLC39A6
|
GM-26839AB
|
Anti-H_SLC39A6 hIgG1 Antibody(Ladiratuzumab)
|
|
SIGLEC9
|
GM-31414AB
|
Anti-siglec9 mIgG1 Antibody(2D4)
|
|
VTCN1(B7H4)
|
GM-24028AB
|
Anti-H_B7H4(VTCN1) hIgG1 Antibody(FPA150)
|
|
VTCN1(B7H4)
|
GM-86662MAB
|
Anti-H_B7H4 hIgG1 Reference Antibody(FPA150)
|
免疫檢查點（checkpoint）是指在免疫細胞上表達、能調節免疫激活程度的一系列分子，它們對防止自身免疫（免疫功能發生異常，對正常細胞發動攻擊）作用的發生，起著重要作用。
人體的免疫功能收到激發時會活化，但不會過度活化，因為”免疫檢查點分子“的重要功能之一就是類似汽車的剎車系統，在免疫系統活化時能夠及時”剎車“，使免疫系統的活化保持在正常的范圍之內，這樣，免疫系統就不會過度活化。
免疫檢查點分子的表達和功能異常是很多疾病發生的重要原因之一，比如免疫檢查點分子過度表達或功能過強，免疫功能受到抑制，機體的免疫力就低下；反之，免疫檢查點分子的這種免疫抑制功能如果太差，機體的免疫功能也會異常。
腫瘤細胞會表達一些物質，來激活免疫檢查點，后者一旦被激活，就如同踩下”剎車“，使抗原不能被提呈至T細胞，阻斷了腫瘤免疫環中的提呈抗原過程，從而抑制T細胞的免疫功能，自己就能逃脫監視、存活下來。
